

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.2	69.5	(22.4-162.2)	Male	7	4.7	149.5	(59.9-308.0)
Female	1	2.2	nc	(nc-nc)	Female	7	3.2	220.8	(88.4-454.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	32	27.3	117.2	(80.1-165.4)	Female	5	3.1	159.9	(51.5-373.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	3	7.6	nc	(nc-nc)	<u>Ovary</u>				
Female	3	6.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	23.9	100.4	(64.3-149.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.7	nc	(nc-nc)
Male	6	2.8	215.6	(78.7-469.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	10	6.1	163.9	(78.5-301.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.8	nc	(nc-nc)	Male	69	94.6	72.9	(56.7-92.3)
Female	1	0.8	nc	(nc-nc)	Female	82	87.0	94.2	(74.9-116.9)
<u>Lung and Bronchus</u>									
Male	6	13.3	45.3	(16.5-98.5)					
Female	1	11.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	14.9	147.5	(92.4-223.4)	Male	11	9.3	118.2	(58.9-211.5)
Female	9	5.4	165.7	(75.6-314.6)	Female	11	7.3	150.0	(74.8-268.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.6	nc	(nc-nc)	Male	6	3.0	199.4	(72.8-434.0)
Female	0	2.4	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	48	61.8	77.7	(57.3-103.0)	Female	7	7.5	93.8	(37.6-193.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	7	6.8	103.5	(41.5-213.3)
<u>Colon / Rectum</u>					Female	2	3.3	nc	(nc-nc)
Male	16	15.2	105.4	(60.2-171.2)	<u>Ovary</u>				
Female	15	15.2	98.5	(55.1-162.4)	Female	1	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.7	162.5	(59.4-353.8)	Male	7	5.5	128.3	(51.4-264.3)
Female	1	1.1	nc	(nc-nc)	Female	2	5.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	28	44.0	63.6	(42.3-92.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	4	8.3	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	6	4.9	122.6	(44.8-266.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.5	143.9	(46.4-335.8)
<u>Leukemia</u>					Female	6	10.5	57.3	(20.9-124.7)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	18	14.4	125.2	(74.2-197.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.1	nc	(nc-nc)	Male	170	185.1	91.8	(78.5-106.7)
Female	1	1.8	nc	(nc-nc)	Female	192	203.8	94.2	(81.4-108.5)
<u>Lung and Bronchus</u>									
Male	33	26.2	126.2	(86.8-177.2)					
Female	44	28.9	152.0	(110.5-204.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	9	6.3	142.4	(65.0-270.3)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.3	94.7	(30.5-221.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	26	22.0	118.1	(77.1-173.1)
Female	0	0.2	nc	(nc-nc)	Female	26	21.4	121.5	(79.4-178.1)
<u>Lung and Bronchus</u>									
Male	3	3.2	nc	(nc-nc)					
Female	2	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	13.4	142.3	(85.6-222.2)	Male	6	8.9	67.5	(24.6-146.9)
Female	5	4.5	111.7	(36.0-260.6)	Female	4	7.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	7.9	114.1	(52.1-216.6)
Female	50	57.9	86.3	(64.1-113.8)	Female	7	6.6	106.0	(42.5-218.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.0	nc	(nc-nc)
Male	7	14.9	46.9	(18.8-96.6)	<u>Ovary</u>				
Female	16	13.7	116.9	(66.8-189.8)	Female	5	4.9	101.6	(32.7-237.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	9	5.1	177.1	(80.8-336.3)
Female	0	0.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	33	42.0	78.7	(54.1-110.5)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.2	nc	(nc-nc)
Male	12	8.3	144.8	(74.7-253.0)	Female	1	1.9	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	11.5	147.4	(85.8-236.0)
Male	7	5.6	125.6	(50.3-258.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.9	nc	(nc-nc)	Female	9	13.3	67.9	(31.0-128.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.0	nc	(nc-nc)	Male	153	176.5	86.7	(73.5-101.6)
Female	1	1.6	nc	(nc-nc)	Female	177	185.5	95.4	(81.9-110.6)
<u>Lung and Bronchus</u>									
Male	21	23.1	90.9	(56.3-139.0)					
Female	22	23.3	94.6	(59.2-143.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.3	71.9	(35.8-128.7)	Male	25	8.7	288.1	(186.4-425.4)
Female	11	4.8	228.7	(114.0-409.2)	Female	15	5.2	288.5	(161.4-475.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.6	144.5	(72.0-258.6)
Female	40	43.5	92.0	(65.8-125.3)	Female	6	5.9	101.4	(37.0-220.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	8	5.7	140.8	(60.6-277.5)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	18	14.0	128.4	(76.0-202.9)	<u>Ovary</u>				
Female	11	12.5	88.3	(44.0-158.0)	Female	4	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	6	5.3	113.4	(41.4-246.9)
Female	1	0.9	nc	(nc-nc)	Female	5	5.0	99.9	(32.2-233.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	39	39.8	98.0	(69.7-134.0)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.3	nc	(nc-nc)
Male	6	7.2	83.7	(30.6-182.1)	Female	1	1.8	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.6	nc	(nc-nc)
Male	9	5.3	170.1	(77.6-322.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	9	10.3	87.7	(40.0-166.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.5	nc	(nc-nc)	Male	175	172.0	101.7	(87.2-118.0)
Female	3	1.5	nc	(nc-nc)	Female	164	154.8	105.9	(90.4-123.5)
<u>Lung and Bronchus</u>									
Male	17	26.4	64.5	(37.5-103.2)					
Female	26	25.4	102.5	(66.9-150.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	40.8	127.4	(95.1-167.0)	Male	21	26.4	79.6	(49.3-121.7)
Female	15	15.8	94.7	(52.9-156.2)	Female	22	21.3	103.4	(64.8-156.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.6	158.2	(81.6-276.4)	Male	7	8.4	83.2	(33.3-171.5)
Female	5	6.8	73.3	(23.6-171.1)	Female	9	7.4	122.4	(55.8-232.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	27	23.2	116.5	(76.8-169.5)
Female	179	174.6	102.5	(88.1-118.7)	Female	10	21.5	46.5	(22.3-85.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.5	90.6	(29.2-211.5)	Male	22	19.5	112.9	(70.8-171.0)
<u>Colon / Rectum</u>					Female	7	9.4	74.1	(29.7-152.7)
Male	39	42.9	91.0	(64.7-124.4)	<u>Ovary</u>				
Female	51	44.1	115.5	(86.0-151.9)	Female	23	14.9	154.5	(97.9-231.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	10.3	87.3	(39.9-165.8)	Male	19	15.2	125.4	(75.4-195.8)
Female	2	3.1	nc	(nc-nc)	Female	24	16.4	146.7	(94.0-218.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	129	121.7	106.0	(88.5-125.9)
Female	3	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	9.6	52.0	(16.8-121.4)
Male	22	23.6	93.0	(58.3-140.9)	Female	3	6.2	nc	(nc-nc)
Female	13	14.1	92.3	(49.1-157.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.4	130.4	(52.2-268.7)
Male	4	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	2.0	nc	(nc-nc)	Male	11	10.5	104.3	(52.0-186.7)
<u>Leukemia</u>					Female	33	30.5	108.1	(74.4-151.8)
Male	16	16.3	98.1	(56.1-159.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	12.4	186.0	(117.9-279.1)	Female	47	39.8	118.2	(86.8-157.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	14.5	103.6	(57.9-170.8)	Male	531	519.3	102.2	(93.7-111.3)
Female	2	5.2	nc	(nc-nc)	Female	608	584.3	104.1	(96.0-112.7)
<u>Lung and Bronchus</u>									
Male	60	71.9	83.4	(63.7-107.4)					
Female	71	84.8	83.7	(65.4-105.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	24.4	73.7	(43.6-116.4)	Male	8	17.2	46.4	(20.0-91.4)
Female	9	8.8	101.7	(46.4-193.1)	Female	11	14.7	74.9	(37.3-134.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.2	96.4	(35.2-209.8)	Male	8	5.2	153.1	(65.9-301.6)
Female	6	5.1	117.0	(42.7-254.7)	Female	3	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	15.7	89.4	(48.8-149.9)
Female	99	109.3	90.5	(73.6-110.2)	Female	19	13.0	146.0	(87.9-228.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.3	209.9	(95.8-398.4)	Male	7	12.8	54.5	(21.8-112.3)
<u>Colon / Rectum</u>					Female	9	5.8	155.5	(71.0-295.2)
Male	33	28.3	116.6	(80.2-163.7)	<u>Ovary</u>				
Female	12	26.6	45.1	(23.3-78.8)	Female	5	9.4	53.1	(17.1-123.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.2	nc	(nc-nc)	Male	9	9.2	97.5	(44.5-185.0)
Female	1	1.8	nc	(nc-nc)	Female	16	9.3	172.4	(98.5-280.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.2	nc	(nc-nc)	Male	52	71.5	72.7	(54.3-95.3)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.0	133.6	(57.5-263.3)
Male	7	15.8	44.3	(17.7-91.2)	Female	4	3.8	nc	(nc-nc)
Female	12	8.6	139.3	(71.9-243.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	7.1	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	13	8.9	145.5	(77.4-248.9)
<u>Leukemia</u>					Female	43	25.9	166.3	(120.3-224.0)
Male	10	11.7	85.6	(41.0-157.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	8.4	142.0	(73.3-248.1)	Female	16	23.6	67.8	(38.7-110.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	8.8	136.1	(70.2-237.7)	Male	301	332.2	90.6	(80.7-101.4)
Female	12	3.0	396.7	(204.7-692.9)	Female	396	364.7	108.6	(98.2-119.8)
<u>Lung and Bronchus</u>									
Male	53	41.6	127.5	(95.5-166.8)					
Female	65	46.5	139.8	(107.9-178.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.2	96.0	(30.9-224.0)	Male	6	3.2	189.7	(69.3-412.9)
Female	2	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	18	17.3	104.0	(61.6-164.3)	Female	4	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	6	5.1	117.8	(43.0-256.3)	<u>Ovary</u>				
Female	2	4.1	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	13	15.7	83.0	(44.1-141.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.0	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.1	122.7	(39.5-286.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	55	63.7	86.3	(65.0-112.3)
Female	0	0.5	nc	(nc-nc)	Female	49	57.3	85.5	(63.3-113.1)
<u>Lung and Bronchus</u>									
Male	12	9.2	130.0	(67.1-227.1)					
Female	6	8.5	71.0	(25.9-154.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	5.5	91.6	(29.5-213.7)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	5	1.7	289.7	(93.3-675.9)	<u>Ovary</u>				
Female	1	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.3	94.3	(30.4-220.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	20	21.2	94.2	(57.5-145.6)
Female	0	0.1	nc	(nc-nc)	Female	15	16.7	89.7	(50.2-147.9)
<u>Lung and Bronchus</u>									
Male	2	2.7	nc	(nc-nc)					
Female	4	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	6.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.8	125.9	(46.0-273.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	22	18.0	122.2	(76.6-185.1)
Female	0	0.2	nc	(nc-nc)	Female	11	19.3	57.1	(28.5-102.1)
<u>Lung and Bronchus</u>									
Male	2	2.2	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	65.0	87.6	(66.4-113.5)	Male	21	40.9	51.3	(31.7-78.4)
Female	21	24.1	87.0	(53.8-133.0)	Female	20	31.9	62.7	(38.3-96.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.1	58.0	(23.2-119.5)	Male	11	13.2	83.3	(41.6-149.1)
Female	11	10.4	106.0	(52.8-189.6)	Female	6	11.1	54.1	(19.8-117.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	30	36.3	82.7	(55.8-118.1)
Female	260	254.6	102.1	(90.1-115.3)	Female	39	32.4	120.4	(85.6-164.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	7.9	139.7	(69.6-249.9)	Male	30	29.6	101.4	(68.4-144.8)
<u>Colon / Rectum</u>					Female	22	14.2	155.0	(97.1-234.6)
Male	95	66.5	142.8	(115.5-174.5)	<u>Ovary</u>				
Female	60	67.7	88.7	(67.7-114.1)	Female	28	22.3	125.6	(83.4-181.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	16.1	99.1	(56.6-161.0)	Male	19	23.8	80.0	(48.1-124.9)
Female	6	4.7	128.5	(46.9-279.7)	Female	24	25.2	95.3	(61.0-141.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.7	nc	(nc-nc)	Male	121	189.5	63.8	(53.0-76.3)
Female	1	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	15.1	73.1	(36.4-130.7)
Male	43	36.2	118.8	(85.9-160.0)	Female	9	9.5	94.4	(43.1-179.2)
Female	28	20.7	135.0	(89.7-195.2)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.6	116.0	(55.5-213.3)
Male	11	9.4	117.6	(58.6-210.4)	<u>Thyroid</u>				
Female	2	2.9	nc	(nc-nc)	Male	13	15.8	82.1	(43.7-140.5)
<u>Leukemia</u>					Female	34	44.8	75.9	(52.5-106.0)
Male	23	25.9	88.9	(56.3-133.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	19.0	52.7	(25.2-96.9)	Female	54	58.5	92.3	(69.3-120.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	22.1	58.7	(31.2-100.4)	Male	722	811.6	89.0	(82.6-95.7)
Female	7	7.9	88.5	(35.5-182.4)	Female	866	870.7	99.5	(92.9-106.3)
<u>Lung and Bronchus</u>									
Male	135	113.3	119.2	(99.9-141.1)					
Female	136	125.6	108.3	(90.8-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	6.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	3	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	19.6	71.6	(39.1-120.1)
Female	0	0.2	nc	(nc-nc)	Female	11	19.8	55.5	(27.7-99.4)
<u>Lung and Bronchus</u>									
Male	3	2.7	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	5	8.8	57.0	(18.4-132.9)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.6	105.5	(45.4-207.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	28	33.4	83.9	(55.8-121.3)
Female	0	0.3	nc	(nc-nc)	Female	23	29.2	78.9	(50.0-118.4)
<u>Lung and Bronchus</u>									
Male	5	4.9	101.3	(32.6-236.3)					
Female	5	4.3	115.5	(37.2-269.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	12.4	217.5	(143.3-316.5)	Male	10	8.3	120.5	(57.7-221.6)
Female	5	5.1	98.4	(31.7-229.6)	Female	12	7.3	165.5	(85.4-289.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.4	67.6	(21.8-157.9)
Female	56	57.4	97.6	(73.7-126.7)	Female	9	7.0	127.7	(58.3-242.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.9	nc	(nc-nc)	Male	5	6.2	80.0	(25.8-186.7)
<u>Colon / Rectum</u>					Female	5	3.1	159.5	(51.4-372.2)
Male	20	13.5	148.1	(90.5-228.8)	<u>Ovary</u>				
Female	12	14.7	81.6	(42.1-142.6)	Female	7	5.0	140.8	(56.4-290.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	56	39.0	143.7	(108.6-186.7)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	13	7.6	170.2	(90.5-291.0)	Female	2	2.1	nc	(nc-nc)
Female	6	4.6	131.0	(47.9-285.2)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	14	11.1	126.5	(69.1-212.2)
Male	8	5.3	151.0	(65.0-297.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.2	165.8	(66.4-341.6)	Female	16	13.0	123.0	(70.2-199.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	4.5	242.5	(120.9-433.9)	Male	216	164.7	131.1	(114.2-149.9)
Female	0	1.7	nc	(nc-nc)	Female	216	192.7	112.1	(97.7-128.1)
<u>Lung and Bronchus</u>									
Male	29	21.8	133.1	(89.1-191.2)					
Female	31	26.3	117.9	(80.1-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.0	100.1	(45.7-190.0)	Male	4	6.0	nc	(nc-nc)
Female	6	3.4	179.0	(65.4-389.5)	Female	15	4.8	314.7	(176.0-519.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.2	114.4	(41.8-249.1)
Female	44	39.4	111.6	(81.1-149.8)	Female	2	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	6	4.4	137.3	(50.1-298.8)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	10	9.5	105.5	(50.5-194.0)	<u>Ovary</u>				
Female	4	9.5	nc	(nc-nc)	Female	5	3.3	151.6	(48.8-353.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	28	26.4	105.9	(70.3-153.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	6	5.3	113.5	(41.5-247.1)	Female	0	1.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.3	136.6	(65.4-251.3)
Male	3	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.7	183.6	(59.2-428.5)	Female	7	8.5	82.1	(32.9-169.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	105	115.5	90.9	(74.4-110.1)
Female	1	1.1	nc	(nc-nc)	Female	132	128.7	102.6	(85.8-121.6)
<u>Lung and Bronchus</u>									
Male	11	16.0	68.9	(34.3-123.2)					
Female	12	18.1	66.4	(34.3-116.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	13	8.5	153.6	(81.7-262.7)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	19	31.8	59.8	(36.0-93.4)
Female	0	0.3	nc	(nc-nc)	Female	34	27.5	123.8	(85.7-173.0)
<u>Lung and Bronchus</u>									
Male	4	4.4	nc	(nc-nc)					
Female	4	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.4	117.0	(80.0-165.1)	Male	27	17.4	155.5	(102.4-226.2)
Female	11	9.7	113.8	(56.7-203.6)	Female	30	12.2	246.4	(166.2-351.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	103.0	(33.2-240.3)	Male	5	5.6	88.5	(28.5-206.6)
Female	4	3.8	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	15	15.3	98.0	(54.8-161.6)
Female	130	99.3	130.9	(109.3-155.4)	Female	10	12.8	78.1	(37.4-143.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	11	12.9	85.6	(42.7-153.1)
<u>Colon / Rectum</u>					Female	8	5.6	143.8	(61.9-283.3)
Male	17	28.6	59.5	(34.6-95.2)	<u>Ovary</u>				
Female	30	27.2	110.1	(74.3-157.2)	Female	16	8.6	185.4	(105.9-301.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	6.9	nc	(nc-nc)	Male	8	10.1	79.3	(34.2-156.3)
Female	0	1.9	nc	(nc-nc)	Female	8	10.2	78.7	(33.9-155.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	82	81.0	101.2	(80.5-125.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.4	nc	(nc-nc)
Male	6	15.7	38.3	(14.0-83.4)	Female	0	3.8	nc	(nc-nc)
Female	11	8.1	136.3	(67.9-243.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.1	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	6	6.8	88.4	(32.3-192.4)
<u>Leukemia</u>					Female	17	15.9	106.8	(62.2-171.0)
Male	10	10.6	94.0	(45.0-172.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	7.3	nc	(nc-nc)	Female	26	22.8	114.2	(74.6-167.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.5	74.0	(29.6-152.4)	Male	285	343.6	82.9	(73.6-93.2)
Female	3	3.1	nc	(nc-nc)	Female	377	339.5	111.0	(100.1-122.8)
<u>Lung and Bronchus</u>									
Male	18	47.7	37.8	(22.4-59.7)					
Female	29	49.2	59.0	(39.5-84.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	10.3	68.0	(27.2-140.0)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	27	33.1	81.5	(53.7-118.6)
Female	0	0.3	nc	(nc-nc)	Female	18	32.1	56.2	(33.3-88.8)
<u>Lung and Bronchus</u>									
Male	3	4.5	nc	(nc-nc)					
Female	1	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	9	5.1	177.0	(80.8-336.1)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	5	1.4	367.6	(118.5-857.8)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	15	15.4	97.3	(54.4-160.6)
Female	1	0.2	nc	(nc-nc)	Female	21	17.2	122.1	(75.5-186.6)
<u>Lung and Bronchus</u>									
Male	2	2.2	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.2	78.1	(33.6-154.0)	Male	6	6.2	97.4	(35.6-211.9)
Female	4	3.5	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	24	36.2	66.2	(42.4-98.5)	Female	2	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	7	10.2	68.8	(27.6-141.7)	<u>Ovary</u>				
Female	8	9.9	80.8	(34.8-159.2)	Female	3	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	22	26.1	84.4	(52.9-127.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.3	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	5.7	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	7	8.2	85.6	(34.3-176.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.2	nc	(nc-nc)	Male	91	119.1	76.4	(61.5-93.8)
Female	0	1.1	nc	(nc-nc)	Female	90	123.8	72.7	(58.5-89.4)
<u>Lung and Bronchus</u>									
Male	18	17.3	104.2	(61.7-164.7)					
Female	15	18.3	82.2	(46.0-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	37.2	88.6	(61.0-124.5)	Male	15	22.8	65.9	(36.8-108.7)
Female	18	13.7	131.8	(78.1-208.3)	Female	15	17.3	86.7	(48.5-143.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	6.2	192.3	(99.3-336.0)	Male	2	7.3	nc	(nc-nc)
Female	5	5.5	90.5	(29.2-211.3)	Female	3	6.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	16	20.1	79.6	(45.5-129.3)
Female	150	136.9	109.6	(92.7-128.6)	Female	21	17.9	117.4	(72.6-179.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.3	nc	(nc-nc)	Male	20	15.8	126.9	(77.5-195.9)
<u>Colon / Rectum</u>					Female	9	7.7	116.5	(53.2-221.2)
Male	34	37.3	91.2	(63.1-127.4)	<u>Ovary</u>				
Female	36	38.7	93.0	(65.2-128.8)	Female	13	11.9	108.9	(57.9-186.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.8	113.4	(54.3-208.5)	Male	15	13.3	112.8	(63.1-186.0)
Female	3	2.6	nc	(nc-nc)	Female	12	14.4	83.2	(42.9-145.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	97	100.1	96.9	(78.6-118.3)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	8.4	71.1	(25.9-154.7)
Male	20	19.5	102.6	(62.7-158.5)	Female	6	5.5	109.6	(40.0-238.6)
Female	16	11.2	142.4	(81.3-231.2)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.0	173.9	(69.7-358.3)
Male	4	5.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.5	nc	(nc-nc)	Male	9	8.3	108.6	(49.5-206.1)
<u>Leukemia</u>					Female	31	23.1	134.0	(91.1-190.3)
Male	9	14.2	63.3	(28.9-120.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	10.7	121.7	(64.7-208.1)	Female	41	30.4	134.9	(96.8-183.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	11.9	58.6	(23.5-120.8)	Male	424	444.2	95.5	(86.6-105.0)
Female	2	4.4	nc	(nc-nc)	Female	505	475.2	106.3	(97.2-116.0)
<u>Lung and Bronchus</u>									
Male	63	63.3	99.5	(76.4-127.3)					
Female	65	68.8	94.5	(72.9-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	42.2	125.6	(94.0-164.2)	Male	23	25.8	89.2	(56.5-133.9)
Female	17	15.5	110.0	(64.0-176.1)	Female	11	19.5	56.5	(28.2-101.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.4	94.5	(37.8-194.6)	Male	5	8.3	60.4	(19.5-140.9)
Female	6	6.5	92.7	(33.8-201.7)	Female	7	7.0	99.9	(40.0-205.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	22	22.9	96.1	(60.2-145.5)
Female	134	155.4	86.2	(72.3-102.1)	Female	17	20.3	83.9	(48.8-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	18	18.1	99.2	(58.8-156.8)
<u>Colon / Rectum</u>					Female	6	8.9	67.7	(24.7-147.4)
Male	38	42.3	89.8	(63.5-123.2)	<u>Ovary</u>				
Female	48	43.6	110.1	(81.2-146.0)	Female	9	13.6	66.1	(30.2-125.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	10.1	128.8	(68.5-220.3)	Male	15	15.1	99.4	(55.6-164.0)
Female	2	3.0	nc	(nc-nc)	Female	7	16.4	42.6	(17.0-87.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.9	nc	(nc-nc)	Male	127	117.2	108.3	(90.3-128.9)
Female	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	9.6	135.7	(72.2-232.0)
Male	21	22.3	94.1	(58.2-143.9)	Female	12	6.1	195.5	(100.9-341.5)
Female	15	12.7	117.9	(65.9-194.5)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.8	nc	(nc-nc)
Male	8	5.8	138.3	(59.5-272.5)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	10	9.4	106.2	(50.8-195.3)
<u>Leukemia</u>					Female	36	25.9	138.8	(97.2-192.2)
Male	15	16.4	91.5	(51.2-150.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	12.0	74.8	(34.1-142.0)	Female	27	35.3	76.5	(50.4-111.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	13.6	102.7	(56.1-172.4)	Male	511	510.0	100.2	(91.7-109.3)
Female	1	4.9	nc	(nc-nc)	Female	450	539.7	83.4	(75.9-91.5)
<u>Lung and Bronchus</u>									
Male	72	72.4	99.4	(77.8-125.2)					
Female	50	78.3	63.9	(47.4-84.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.2	102.7	(70.2-145.0)	Male	25	18.9	132.1	(85.5-195.0)
Female	15	12.9	116.3	(65.0-191.8)	Female	21	15.8	132.5	(82.0-202.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.4	148.3	(63.9-292.3)	Male	7	6.1	115.6	(46.3-238.2)
Female	6	5.1	117.6	(43.0-256.0)	Female	4	5.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	24	16.9	142.3	(91.2-211.8)
Female	152	123.0	123.6	(104.7-144.9)	Female	18	16.6	108.1	(64.1-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	19	12.9	147.1	(88.5-229.8)
<u>Colon / Rectum</u>					Female	11	7.1	155.2	(77.4-277.7)
Male	29	31.2	93.0	(62.3-133.5)	<u>Ovary</u>				
Female	35	36.5	95.9	(66.8-133.4)	Female	6	11.0	54.7	(20.0-119.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.3	nc	(nc-nc)	Male	17	11.0	153.9	(89.6-246.4)
Female	3	2.4	nc	(nc-nc)	Female	17	13.6	125.0	(72.8-200.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.0	nc	(nc-nc)	Male	89	82.8	107.5	(86.4-132.3)
Female	4	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.0	113.7	(49.0-224.1)
Male	25	16.1	155.3	(100.4-229.2)	Female	7	5.1	136.8	(54.8-282.0)
Female	14	10.3	135.5	(74.0-227.3)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.9	154.9	(56.6-337.2)
Male	5	4.2	119.8	(38.6-279.5)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	6	7.0	86.0	(31.4-187.2)
<u>Leukemia</u>					Female	25	20.6	121.1	(78.3-178.7)
Male	12	12.1	99.5	(51.4-173.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.1	79.5	(34.2-156.6)	Female	27	27.1	99.7	(65.7-145.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.8	112.4	(56.0-201.1)	Male	419	370.3	113.2	(102.6-124.5)
Female	5	4.1	122.7	(39.5-286.3)	Female	494	436.5	113.2	(103.4-123.6)
<u>Lung and Bronchus</u>									
Male	49	52.4	93.5	(69.2-123.6)					
Female	81	64.2	126.1	(100.2-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.6	nc	(nc-nc)	Male	6	3.3	179.7	(65.6-391.1)
Female	3	2.3	nc	(nc-nc)	Female	5	3.2	156.6	(50.5-365.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	19	26.4	72.0	(43.3-112.4)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	8	5.4	148.3	(63.8-292.2)	<u>Ovary</u>				
Female	7	6.5	108.0	(43.3-222.6)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	17.0	94.1	(53.7-152.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.7	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	9	6.2	145.4	(66.3-276.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	60	66.8	89.8	(68.5-115.6)
Female	0	0.8	nc	(nc-nc)	Female	71	86.8	81.8	(63.9-103.1)
<u>Lung and Bronchus</u>									
Male	4	8.6	nc	(nc-nc)					
Female	9	12.1	74.2	(33.8-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	32.0	159.6	(118.8-209.9)	Male	37	18.0	205.5	(144.7-283.3)
Female	16	11.6	138.4	(79.1-224.8)	Female	27	12.7	213.3	(140.5-310.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.4	nc	(nc-nc)	Male	11	6.0	183.2	(91.3-327.9)
Female	1	4.0	nc	(nc-nc)	Female	5	5.1	97.5	(31.4-227.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	15.7	82.7	(44.0-141.4)
Female	116	107.3	108.1	(89.3-129.7)	Female	12	14.4	83.1	(42.9-145.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	14	11.6	120.6	(65.9-202.3)
<u>Colon / Rectum</u>					Female	3	6.2	nc	(nc-nc)
Male	23	28.7	80.0	(50.7-120.1)	<u>Ovary</u>				
Female	25	29.5	84.8	(54.8-125.1)	Female	19	9.4	203.1	(122.2-317.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.3	164.4	(84.9-287.3)	Male	9	11.0	81.8	(37.3-155.3)
Female	6	2.2	267.4	(97.7-582.1)	Female	12	11.9	100.7	(52.0-175.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	100	83.5	119.7	(97.4-145.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.9	nc	(nc-nc)
Male	6	14.8	40.5	(14.8-88.1)	Female	2	4.2	nc	(nc-nc)
Female	7	9.2	76.4	(30.6-157.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.8	94.1	(50.1-160.9)
Male	10	11.1	90.2	(43.2-165.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.0	87.4	(35.0-180.2)	Female	22	25.8	85.1	(53.3-128.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.3	85.9	(37.0-169.2)	Male	391	358.5	109.1	(98.5-120.4)
Female	2	3.6	nc	(nc-nc)	Female	394	377.3	104.4	(94.4-115.3)
<u>Lung and Bronchus</u>									
Male	48	55.9	85.9	(63.4-113.9)					
Female	63	61.9	101.8	(78.2-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.9	126.3	(60.5-232.4)	Male	8	5.3	149.8	(64.5-295.2)
Female	0	2.9	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.7	106.8	(34.4-249.3)
Female	26	31.4	82.8	(54.1-121.4)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	11	8.8	124.4	(62.0-222.7)	<u>Ovary</u>				
Female	8	8.2	97.3	(41.9-191.7)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	21	24.4	86.1	(53.3-131.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	5	4.9	101.3	(32.6-236.3)	Female	1	1.2	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.6	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.4	nc	(nc-nc)	Female	9	7.1	127.2	(58.0-241.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.0	nc	(nc-nc)	Male	110	104.6	105.1	(86.4-126.7)
Female	2	1.0	nc	(nc-nc)	Female	91	106.3	85.6	(68.9-105.1)
<u>Lung and Bronchus</u>									
Male	10	14.1	70.9	(33.9-130.3)					
Female	15	15.2	98.9	(55.3-163.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.2	134.8	(67.2-241.2)	Male	12	5.7	211.0	(108.9-368.6)
Female	6	2.3	263.7	(96.3-574.0)	Female	2	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	5	1.9	268.8	(86.6-627.2)
Female	1	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.1	(31.9-231.3)
Female	33	35.3	93.6	(64.4-131.4)	Female	1	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	4.5	132.7	(48.5-288.9)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	8	9.1	87.4	(37.7-172.3)	<u>Ovary</u>				
Female	9	7.0	128.6	(58.7-244.1)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	25	27.5	90.9	(58.8-134.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	6	5.4	111.4	(40.7-242.4)	Female	0	1.0	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	5	2.5	196.1	(63.2-457.6)
<u>Leukemia</u>					Female	8	7.5	107.3	(46.2-211.4)
Male	3	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	6	7.9	75.5	(27.6-164.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	123	113.1	108.7	(90.4-129.7)
Female	0	0.9	nc	(nc-nc)	Female	104	106.5	97.7	(79.8-118.3)
<u>Lung and Bronchus</u>									
Male	16	15.0	106.4	(60.8-172.7)					
Female	13	13.2	98.4	(52.3-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.0	nc	(nc-nc)	Male	10	4.9	202.3	(96.9-372.1)
Female	2	2.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	4.3	161.2	(64.6-332.2)
Female	31	27.7	111.8	(76.0-158.7)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	7	8.2	85.7	(34.3-176.5)	<u>Ovary</u>				
Female	2	6.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	22.2	99.1	(62.1-150.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	5	4.3	115.2	(37.1-268.9)	Female	0	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.2	116.0	(42.3-252.4)
Male	1	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	5	6.2	81.3	(26.2-189.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.6	nc	(nc-nc)	Male	88	96.9	90.8	(72.8-111.9)
Female	0	0.7	nc	(nc-nc)	Female	72	86.4	83.4	(65.2-105.0)
<u>Lung and Bronchus</u>									
Male	8	13.9	57.7	(24.8-113.6)					
Female	6	11.4	52.8	(19.3-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	30.5	114.9	(80.0-159.8)	Male	15	20.3	73.8	(41.3-121.7)
Female	17	10.6	160.5	(93.4-256.9)	Female	17	16.0	106.4	(61.9-170.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.3	142.3	(64.9-270.1)	Male	9	6.5	138.6	(63.3-263.2)
Female	3	5.2	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	12	17.9	67.1	(34.6-117.2)
Female	137	129.2	106.1	(89.0-125.4)	Female	12	15.1	79.2	(40.9-138.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.4	nc	(nc-nc)	Male	16	15.7	101.6	(58.1-165.1)
<u>Colon / Rectum</u>					Female	10	6.9	146.0	(69.9-268.4)
Male	36	32.6	110.4	(77.3-152.9)	<u>Ovary</u>				
Female	44	30.6	143.7	(104.4-192.9)	Female	11	11.1	99.2	(49.4-177.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.1	160.4	(85.3-274.3)	Male	9	11.6	77.8	(35.5-147.8)
Female	4	2.1	nc	(nc-nc)	Female	12	10.9	110.2	(56.9-192.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.6	nc	(nc-nc)	Male	82	99.2	82.7	(65.8-102.6)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	7.3	150.2	(74.9-268.7)
Male	20	18.9	105.9	(64.6-163.5)	Female	5	4.3	116.2	(37.4-271.2)
Female	16	10.2	157.4	(89.9-255.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.9	101.8	(32.8-237.5)
Male	8	4.7	168.9	(72.7-332.8)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	8	8.7	92.3	(39.8-181.9)
<u>Leukemia</u>					Female	24	25.4	94.5	(60.5-140.6)
Male	16	12.8	124.9	(71.3-202.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.9	56.4	(18.2-131.7)	Female	27	29.7	90.8	(59.8-132.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	11.6	103.6	(53.4-180.9)	Male	445	407.5	109.2	(99.3-119.8)
Female	4	3.7	nc	(nc-nc)	Female	472	422.1	111.8	(102.0-122.4)
<u>Lung and Bronchus</u>									
Male	81	55.1	147.1	(116.8-182.8)					
Female	75	57.3	130.9	(103.0-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	11.4	105.0	(54.2-183.4)	Male	5	7.6	65.7	(21.2-153.4)
Female	3	3.3	nc	(nc-nc)	Female	7	5.2	133.4	(53.4-274.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.6	(23.7-171.7)
Female	46	42.8	107.6	(78.8-143.5)	Female	5	4.8	103.9	(33.5-242.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.2	nc	(nc-nc)
Male	11	12.2	90.4	(45.1-161.8)	<u>Ovary</u>				
Female	11	9.9	111.2	(55.4-199.0)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	34	35.1	96.8	(67.0-135.3)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.7	nc	(nc-nc)
Male	16	6.9	232.1	(132.6-377.0)	Female	0	1.4	nc	(nc-nc)
Female	7	3.3	214.8	(86.0-442.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.8	124.5	(62.1-222.8)
Male	9	4.8	186.8	(85.2-354.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	2.9	206.9	(75.6-450.4)	Female	16	9.7	165.5	(94.6-268.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	155	150.2	103.2	(87.6-120.8)
Female	1	1.2	nc	(nc-nc)	Female	172	137.1	125.4	(107.4-145.7)
<u>Lung and Bronchus</u>									
Male	20	20.5	97.4	(59.5-150.5)					
Female	26	17.4	149.3	(97.5-218.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.5	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	14	16.7	83.8	(45.8-140.6)	Female	2	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	5	3.9	129.5	(41.7-302.3)	<u>Ovary</u>				
Female	1	3.8	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	11.4	87.6	(41.9-161.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.7	136.0	(43.8-317.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	42	46.7	89.9	(64.8-121.5)
Female	0	0.4	nc	(nc-nc)	Female	45	51.9	86.8	(63.3-116.1)
<u>Lung and Bronchus</u>									
Male	3	6.2	nc	(nc-nc)					
Female	8	6.5	122.8	(52.9-242.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	19.3	134.5	(87.8-197.0)	Male	31	12.3	251.8	(171.0-357.4)
Female	2	6.4	nc	(nc-nc)	Female	12	9.2	131.0	(67.6-228.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	141.2	(45.5-329.6)	Male	9	4.1	221.5	(101.1-420.5)
Female	1	2.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	18	10.9	164.9	(97.7-260.6)
Female	85	77.2	110.1	(88.0-136.2)	Female	6	8.9	67.2	(24.5-146.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	5	9.6	52.3	(16.9-122.0)
<u>Colon / Rectum</u>					Female	4	4.1	nc	(nc-nc)
Male	3	20.3	nc	(nc-nc)	<u>Ovary</u>				
Female	12	19.0	63.0	(32.5-110.1)	Female	9	6.5	138.5	(63.2-263.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.1	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	8	6.8	118.1	(50.8-232.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	74	62.9	117.6	(92.3-147.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.6	nc	(nc-nc)
Male	16	11.5	138.7	(79.2-225.2)	Female	0	2.6	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	13.6	58.7	(25.3-115.7)
Male	8	7.6	104.7	(45.1-206.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.2	134.8	(54.0-277.7)	Female	11	17.5	63.0	(31.4-112.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	7.1	nc	(nc-nc)	Male	252	251.0	100.4	(88.4-113.6)
Female	0	2.2	nc	(nc-nc)	Female	216	249.5	86.6	(75.4-98.9)
<u>Lung and Bronchus</u>									
Male	27	34.3	78.7	(51.9-114.6)					
Female	22	33.4	65.8	(41.2-99.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.1	113.8	(65.0-184.8)	Male	12	9.3	129.0	(66.6-225.3)
Female	2	6.3	nc	(nc-nc)	Female	10	8.6	116.5	(55.8-214.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.2	109.1	(49.8-207.2)
Female	53	71.1	74.5	(55.8-97.5)	Female	11	8.5	128.8	(64.2-230.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	9	7.0	128.8	(58.8-244.5)
<u>Colon / Rectum</u>					Female	1	3.8	nc	(nc-nc)
Male	19	15.1	125.9	(75.8-196.6)	<u>Ovary</u>				
Female	10	17.6	56.9	(27.2-104.6)	Female	7	6.1	115.2	(46.2-237.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.6	165.2	(60.3-359.6)	Male	3	5.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	7	6.5	108.4	(43.4-223.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	51	43.6	117.0	(87.1-153.8)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.4	nc	(nc-nc)
Male	15	8.6	175.3	(98.1-289.2)	Female	3	2.5	nc	(nc-nc)
Female	5	5.7	87.6	(28.2-204.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.7	86.9	(43.3-155.4)
Male	3	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.0	nc	(nc-nc)	Female	10	16.2	61.9	(29.6-113.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.1	nc	(nc-nc)	Male	199	184.0	108.2	(93.7-124.3)
Female	1	2.1	nc	(nc-nc)	Female	179	235.8	75.9	(65.2-87.9)
<u>Lung and Bronchus</u>									
Male	24	25.1	95.5	(61.2-142.1)					
Female	22	34.0	64.7	(40.5-98.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	6	9.8	61.3	(22.4-133.4)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.4	106.4	(50.9-195.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	5	2.3	214.8	(69.2-501.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.0	nc	(nc-nc)	Male	40	39.7	100.8	(72.0-137.3)
Female	0	0.3	nc	(nc-nc)	Female	29	31.3	92.7	(62.1-133.2)
<u>Lung and Bronchus</u>									
Male	5	5.6	89.3	(28.8-208.4)					
Female	7	4.2	166.7	(66.8-343.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	23.0	60.9	(33.3-102.2)	Male	13	13.7	94.9	(50.5-162.3)
Female	5	8.6	58.1	(18.7-135.6)	Female	11	10.9	101.2	(50.5-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.7	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	12.1	115.3	(63.0-193.5)
Female	80	86.0	93.0	(73.8-115.8)	Female	11	11.3	97.0	(48.3-173.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	10	9.7	103.6	(49.6-190.6)
<u>Colon / Rectum</u>					Female	3	4.9	nc	(nc-nc)
Male	25	22.9	108.9	(70.5-160.8)	<u>Ovary</u>				
Female	33	24.2	136.4	(93.8-191.5)	Female	11	7.5	145.9	(72.8-261.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	7	8.2	85.9	(34.4-176.9)
Female	2	1.6	nc	(nc-nc)	Female	7	9.0	77.4	(31.0-159.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	52	62.8	82.8	(61.9-108.6)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.2	nc	(nc-nc)
Male	14	11.8	118.7	(64.9-199.2)	Female	6	3.4	174.4	(63.7-379.6)
Female	5	7.1	70.8	(22.8-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	14.3	83.7	(43.2-146.2)
Male	4	8.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.7	nc	(nc-nc)	Female	22	19.3	113.8	(71.3-172.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	7.3	nc	(nc-nc)	Male	231	271.7	85.0	(74.4-96.7)
Female	1	2.8	nc	(nc-nc)	Female	288	298.6	96.5	(85.6-108.3)
<u>Lung and Bronchus</u>									
Male	37	38.3	96.7	(68.1-133.2)					
Female	45	43.4	103.7	(75.6-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.9	128.7	(70.3-216.0)	Male	13	6.1	211.5	(112.5-361.7)
Female	1	3.5	nc	(nc-nc)	Female	6	4.0	148.8	(54.3-323.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	93.5	(30.1-218.2)
Female	50	34.2	146.2	(108.5-192.7)	Female	6	4.5	133.7	(48.8-291.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	7	4.2	168.3	(67.4-346.8)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	14	10.0	140.5	(76.7-235.7)	<u>Ovary</u>				
Female	9	9.2	97.8	(44.6-185.7)	Female	3	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	7	3.6	192.8	(77.2-397.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	32	29.7	107.6	(73.6-151.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.4	nc	(nc-nc)
Male	5	5.2	97.0	(31.3-226.4)	Female	3	1.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.8	nc	(nc-nc)
Male	7	3.8	185.0	(74.1-381.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	3	8.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	156	123.9	125.9	(106.9-147.3)
Female	1	1.1	nc	(nc-nc)	Female	127	118.8	106.9	(89.1-127.2)
<u>Lung and Bronchus</u>									
Male	28	18.7	149.5	(99.3-216.1)					
Female	14	19.0	73.7	(40.3-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	19.4	61.7	(31.8-107.8)	Male	10	12.6	79.6	(38.1-146.4)
Female	5	6.8	73.6	(23.7-171.7)	Female	4	9.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	15	11.1	135.6	(75.8-223.6)
Female	75	76.2	98.4	(77.4-123.4)	Female	7	9.4	74.4	(29.8-153.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	10	9.3	107.1	(51.3-196.9)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	26	20.3	127.9	(83.6-187.5)	<u>Ovary</u>				
Female	18	19.3	93.1	(55.1-147.1)	Female	1	6.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	7	7.3	96.5	(38.7-198.8)
Female	1	1.3	nc	(nc-nc)	Female	11	7.0	156.2	(77.9-279.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	45	59.5	75.6	(55.2-101.2)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.6	130.9	(47.8-284.8)
Male	14	11.3	123.8	(67.6-207.8)	Female	2	2.7	nc	(nc-nc)
Female	6	6.1	98.4	(35.9-214.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	14.0	57.1	(24.6-112.4)
Male	5	7.6	65.4	(21.1-152.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.4	nc	(nc-nc)	Female	23	17.7	130.0	(82.4-195.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.0	nc	(nc-nc)	Male	207	249.3	83.0	(72.1-95.1)
Female	5	2.3	215.5	(69.5-503.0)	Female	244	255.3	95.6	(83.9-108.3)
<u>Lung and Bronchus</u>									
Male	26	34.7	74.9	(48.9-109.8)					
Female	43	35.7	120.5	(87.2-162.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	21.9	128.1	(85.1-185.1)	Male	23	14.6	157.8	(100.0-236.8)
Female	12	7.9	151.3	(78.1-264.3)	Female	10	11.9	84.1	(40.3-154.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	130.4	(47.6-283.8)	Male	4	4.7	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	7	3.8	184.1	(73.8-379.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	10	13.0	77.1	(36.9-141.9)
Female	113	98.7	114.5	(94.3-137.6)	Female	12	11.4	105.3	(54.3-183.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	10	11.4	87.8	(42.0-161.5)
<u>Colon / Rectum</u>					Female	5	5.1	97.2	(31.3-226.8)
Male	14	23.7	59.1	(32.3-99.2)	<u>Ovary</u>				
Female	26	22.9	113.5	(74.1-166.4)	Female	11	8.3	132.9	(66.3-237.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.9	nc	(nc-nc)	Male	12	8.3	144.2	(74.4-251.9)
Female	2	1.6	nc	(nc-nc)	Female	12	8.2	147.1	(75.9-256.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.8	nc	(nc-nc)	Male	94	71.8	130.8	(105.7-160.1)
Female	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	17	13.8	123.4	(71.8-197.5)	Female	3	3.2	nc	(nc-nc)
Female	5	7.6	65.4	(21.1-152.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.2	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	6	6.2	96.6	(35.3-210.2)
<u>Leukemia</u>					Female	20	19.1	104.7	(64.0-161.8)
Male	16	9.2	173.0	(98.8-280.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.6	nc	(nc-nc)	Female	21	22.3	94.0	(58.2-143.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	8.3	120.6	(57.7-221.8)	Male	324	293.9	110.2	(98.6-122.9)
Female	5	2.7	182.3	(58.8-425.4)	Female	354	318.7	111.1	(99.8-123.3)
<u>Lung and Bronchus</u>									
Male	34	39.7	85.6	(59.3-119.7)					
Female	50	43.1	115.9	(86.0-152.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.8	87.9	(32.1-191.3)	Male	18	4.3	415.6	(246.2-656.8)
Female	2	1.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.8	130.8	(42.1-305.2)
Female	29	19.9	146.0	(97.8-209.8)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.4	178.4	(65.1-388.3)
<u>Colon / Rectum</u>					Female	3	1.1	nc	(nc-nc)
Male	10	7.1	140.1	(67.1-257.7)	<u>Ovary</u>				
Female	4	5.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	21.7	110.7	(70.9-164.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	3.2	185.5	(67.8-403.9)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	101	87.5	115.4	(94.0-140.2)
Female	1	0.6	nc	(nc-nc)	Female	72	66.4	108.5	(84.9-136.7)
<u>Lung and Bronchus</u>									
Male	13	11.7	110.6	(58.9-189.2)					
Female	9	9.6	93.5	(42.7-177.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	6	7.4	81.5	(29.8-177.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	5	2.6	194.2	(62.6-453.3)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.7	77.9	(28.5-169.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	22	31.7	69.5	(43.5-105.2)
Female	0	0.2	nc	(nc-nc)	Female	25	25.8	96.9	(62.7-143.1)
<u>Lung and Bronchus</u>									
Male	1	4.6	nc	(nc-nc)					
Female	3	4.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	8.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	6.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	26.7	67.3	(39.9-106.4)
Female	0	0.3	nc	(nc-nc)	Female	21	28.7	73.2	(45.3-111.8)
<u>Lung and Bronchus</u>									
Male	5	3.6	140.3	(45.2-327.3)					
Female	3	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.1	nc	(nc-nc)	Male	7	3.2	220.2	(88.2-453.8)
Female	1	1.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	18	17.5	102.8	(60.9-162.5)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	1	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.0	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	16.2	55.6	(25.4-105.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	58	64.8	89.5	(68.0-115.7)
Female	0	0.5	nc	(nc-nc)	Female	59	56.5	104.5	(79.5-134.8)
<u>Lung and Bronchus</u>									
Male	10	8.9	112.3	(53.7-206.5)					
Female	9	8.0	112.8	(51.5-214.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	37.4	85.6	(58.5-120.8)	Male	22	25.0	88.1	(55.2-133.5)
Female	12	13.6	88.0	(45.4-153.7)	Female	9	20.9	43.0	(19.6-81.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	8.0	nc	(nc-nc)	Male	9	7.8	114.7	(52.3-217.7)
Female	4	7.0	nc	(nc-nc)	Female	2	6.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	22	22.2	99.0	(62.0-150.0)
Female	146	161.2	90.6	(76.5-106.5)	Female	17	19.5	87.2	(50.8-139.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	5.9	219.1	(116.5-374.7)	Male	18	18.4	98.0	(58.1-154.9)
<u>Colon / Rectum</u>					Female	11	8.6	127.7	(63.7-228.5)
Male	40	40.0	99.9	(71.4-136.0)	<u>Ovary</u>				
Female	27	40.4	66.8	(44.0-97.2)	Female	12	13.9	86.4	(44.6-150.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.5	115.4	(57.5-206.6)	Male	15	13.9	107.8	(60.3-177.8)
Female	2	2.7	nc	(nc-nc)	Female	13	14.2	91.3	(48.6-156.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.5	nc	(nc-nc)	Male	88	111.1	79.2	(63.5-97.6)
Female	2	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.9	179.6	(102.6-291.6)
Male	26	22.5	115.3	(75.3-169.0)	Female	7	5.7	123.5	(49.5-254.5)
Female	15	12.7	118.0	(66.0-194.6)	<u>Testis</u>				
<u>Larynx</u>					Male	7	7.1	98.6	(39.5-203.1)
Male	8	5.6	143.8	(61.9-283.4)	<u>Thyroid</u>				
Female	5	1.7	294.3	(94.8-686.7)	Male	13	11.0	118.0	(62.8-201.8)
<u>Leukemia</u>					Female	29	34.3	84.7	(56.7-121.6)
Male	17	16.1	105.7	(61.5-169.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	11.8	92.9	(46.3-166.2)	Female	27	35.6	75.9	(50.0-110.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	13.4	164.3	(102.9-248.7)	Male	470	488.5	96.2	(87.7-105.3)
Female	6	4.6	130.1	(47.5-283.1)	Female	478	537.3	89.0	(81.2-97.3)
<u>Lung and Bronchus</u>									
Male	69	66.3	104.0	(80.9-131.6)					
Female	73	71.0	102.8	(80.6-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	22.5	106.8	(68.4-158.9)	Male	8	13.8	58.0	(25.0-114.2)
Female	20	8.6	232.5	(142.0-359.1)	Female	5	10.7	46.5	(15.0-108.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	7	4.4	157.5	(63.1-324.5)
Female	3	3.4	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	12.1	90.6	(45.2-162.2)
Female	80	85.7	93.4	(74.1-116.2)	Female	15	11.2	134.4	(75.1-221.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	5	9.9	50.3	(16.2-117.4)
<u>Colon / Rectum</u>					Female	3	4.9	nc	(nc-nc)
Male	17	22.7	74.8	(43.6-119.8)	<u>Ovary</u>				
Female	22	24.0	91.8	(57.5-139.0)	Female	14	7.6	184.5	(100.8-309.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.5	nc	(nc-nc)	Male	6	8.1	73.9	(27.0-160.8)
Female	2	1.6	nc	(nc-nc)	Female	7	9.0	77.6	(31.1-159.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	62	64.9	95.5	(73.2-122.4)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.1	nc	(nc-nc)
Male	17	12.1	140.2	(81.6-224.5)	Female	3	3.4	nc	(nc-nc)
Female	7	7.1	98.4	(39.4-202.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	5	3.1	159.3	(51.3-371.7)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Leukemia</u>					Female	14	14.0	99.7	(54.5-167.3)
Male	6	8.5	70.2	(25.6-152.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.5	153.1	(73.3-281.7)	Female	18	19.7	91.4	(54.2-144.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	7.5	nc	(nc-nc)	Male	245	274.5	89.3	(78.4-101.2)
Female	1	2.8	nc	(nc-nc)	Female	286	297.9	96.0	(85.2-107.8)
<u>Lung and Bronchus</u>									
Male	39	38.6	101.1	(71.9-138.2)					
Female	36	44.2	81.5	(57.1-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	101	87.6	115.3	(93.9-140.1)	Male	26	56.4	46.1	(30.1-67.6)
Female	37	38.3	96.7	(68.0-133.2)	Female	24	51.4	46.7	(29.9-69.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.2	99.1	(57.7-158.7)	Male	12	17.9	66.9	(34.5-116.9)
Female	14	16.7	83.6	(45.7-140.3)	Female	13	17.5	74.1	(39.4-126.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.1	nc	(nc-nc)	Male	48	50.1	95.8	(70.6-127.0)
Female	317	403.6	78.5	(70.1-87.7)	Female	38	51.5	73.7	(52.2-101.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	13.0	145.7	(87.7-227.5)	Male	38	41.6	91.4	(64.7-125.5)
<u>Colon / Rectum</u>					Female	22	22.4	98.0	(61.4-148.4)
Male	108	92.0	117.4	(96.3-141.7)	<u>Ovary</u>				
Female	115	109.0	105.6	(87.1-126.7)	Female	18	35.3	51.0	(30.2-80.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	22.0	81.9	(48.5-129.4)	Male	35	32.4	108.1	(75.3-150.3)
Female	4	7.4	nc	(nc-nc)	Female	42	40.1	104.7	(75.4-141.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	7.0	143.8	(68.8-264.5)	Male	278	262.7	105.8	(93.8-119.0)
Female	7	6.7	104.2	(41.8-214.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	34	20.6	165.4	(114.5-231.1)
Male	56	50.8	110.2	(83.3-143.1)	Female	28	15.3	182.5	(121.2-263.8)
Female	35	32.9	106.5	(74.2-148.1)	<u>Testis</u>				
<u>Larynx</u>					Male	12	13.4	89.9	(46.4-157.0)
Male	17	12.8	132.7	(77.3-212.6)	<u>Thyroid</u>				
Female	8	4.6	175.2	(75.4-345.2)	Male	16	23.1	69.2	(39.5-112.4)
<u>Leukemia</u>					Female	91	73.9	123.2	(99.2-151.3)
Male	35	35.9	97.4	(67.9-135.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	34	30.7	110.7	(76.6-154.6)	Female	93	90.4	102.9	(83.0-126.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	36	30.5	117.9	(82.5-163.2)	Male	1256	1119.3	112.2	(106.1-118.6)
Female	10	12.4	80.8	(38.7-148.6)	Female	1277	1384.9	92.2	(87.2-97.4)
<u>Lung and Bronchus</u>									
Male	258	153.3	168.3	(148.4-190.2)					
Female	200	197.5	101.3	(87.7-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	57.2	82.1	(60.3-109.2)	Male	36	33.5	107.4	(75.2-148.7)
Female	13	20.9	62.1	(33.0-106.2)	Female	33	24.2	136.5	(93.9-191.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	8.6	162.2	(88.6-272.2)	Male	8	11.0	73.0	(31.4-143.9)
Female	10	7.6	131.2	(62.8-241.3)	Female	10	9.3	107.1	(51.3-197.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	32	29.3	109.1	(74.6-154.1)
Female	204	199.8	102.1	(88.6-117.1)	Female	13	26.5	49.1	(26.1-84.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	28	23.0	121.8	(80.9-176.1)
<u>Colon / Rectum</u>					Female	11	11.5	96.0	(47.9-171.8)
Male	52	54.6	95.2	(71.1-124.8)	<u>Ovary</u>				
Female	52	55.8	93.2	(69.6-122.2)	Female	22	17.5	125.5	(78.6-190.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	13.4	89.5	(46.2-156.4)	Male	14	20.2	69.3	(37.9-116.4)
Female	5	4.0	124.6	(40.1-290.7)	Female	14	21.8	64.2	(35.1-107.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	183	157.1	116.5	(100.2-134.6)
Female	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	12.7	78.7	(37.7-144.7)
Male	29	28.6	101.5	(68.0-145.8)	Female	3	7.9	nc	(nc-nc)
Female	15	16.9	88.9	(49.7-146.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.8	nc	(nc-nc)
Male	13	7.7	168.3	(89.5-287.8)	<u>Thyroid</u>				
Female	2	2.4	nc	(nc-nc)	Male	8	10.5	76.5	(32.9-150.7)
<u>Leukemia</u>					Female	15	28.8	52.1	(29.1-85.9)
Male	29	20.7	140.4	(94.0-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	15.1	39.6	(14.5-86.3)	Female	33	46.5	70.9	(48.8-99.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	17.7	96.1	(56.0-153.9)	Male	665	667.4	99.6	(92.2-107.5)
Female	3	6.5	nc	(nc-nc)	Female	644	699.6	92.1	(85.1-99.4)
<u>Lung and Bronchus</u>									
Male	74	99.3	74.5	(58.5-93.5)					
Female	118	110.2	107.1	(88.6-128.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	39.9	130.4	(97.4-171.0)	Male	17	25.8	66.0	(38.4-105.6)
Female	20	13.8	145.1	(88.6-224.1)	Female	15	19.2	78.2	(43.7-129.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	8.0	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
Female	13	6.6	198.4	(105.5-339.2)	Female	6	6.3	94.8	(34.6-206.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	13	22.9	56.8	(30.2-97.2)
Female	147	151.5	97.0	(82.0-114.1)	Female	15	18.7	80.1	(44.8-132.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.0	160.1	(68.9-315.5)	Male	22	18.7	117.5	(73.6-178.0)
<u>Colon / Rectum</u>					Female	8	8.3	96.5	(41.6-190.2)
Male	40	41.8	95.6	(68.3-130.2)	<u>Ovary</u>				
Female	45	39.5	114.0	(83.1-152.5)	Female	12	13.2	90.7	(46.8-158.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.9	60.4	(22.0-131.4)	Male	17	14.7	115.9	(67.5-185.6)
Female	2	2.6	nc	(nc-nc)	Female	9	14.3	62.8	(28.6-119.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.3	nc	(nc-nc)	Male	84	115.1	73.0	(58.2-90.3)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	9.3	128.4	(66.2-224.2)
Male	27	22.9	117.9	(77.7-171.6)	Female	6	5.5	108.6	(39.7-236.5)
Female	16	12.3	129.8	(74.2-210.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.2	96.0	(35.1-209.0)
Male	4	5.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	8	10.5	75.9	(32.7-149.5)
<u>Leukemia</u>					Female	32	29.1	110.1	(75.3-155.4)
Male	14	16.6	84.4	(46.1-141.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	11.6	147.0	(85.6-235.4)	Female	29	33.5	86.5	(57.9-124.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	13.8	115.9	(66.2-188.3)	Male	478	505.9	94.5	(86.2-103.3)
Female	6	4.5	133.5	(48.7-290.5)	Female	534	514.3	103.8	(95.2-113.0)
<u>Lung and Bronchus</u>									
Male	86	69.8	123.1	(98.5-152.1)					
Female	76	72.7	104.6	(82.4-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	10.9	92.1	(44.1-169.5)
Female	0	0.1	nc	(nc-nc)	Female	8	12.6	63.5	(27.3-125.2)
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	21.3	75.1	(42.9-121.9)	Male	24	13.2	182.3	(116.7-271.2)
Female	1	7.2	nc	(nc-nc)	Female	11	9.9	111.1	(55.4-198.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.7	216.7	(93.3-427.0)	Male	2	4.2	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.7	93.9	(46.8-168.0)
Female	98	80.1	122.3	(99.3-149.1)	Female	7	9.8	71.2	(28.5-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	8	9.4	85.4	(36.8-168.4)
<u>Colon / Rectum</u>					Female	2	4.4	nc	(nc-nc)
Male	20	22.0	91.1	(55.6-140.7)	<u>Ovary</u>				
Female	20	20.4	98.0	(59.8-151.4)	Female	6	6.9	87.1	(31.8-189.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.1	116.9	(42.7-254.4)	Male	4	7.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	6	7.5	80.3	(29.3-174.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.4	364.5	(117.5-850.5)	Male	63	58.3	108.1	(83.0-138.2)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	4.9	163.8	(70.5-322.8)
Male	19	11.4	166.7	(100.3-260.3)	Female	3	2.9	nc	(nc-nc)
Female	8	6.4	124.6	(53.7-245.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.0	139.2	(55.8-286.8)
<u>Leukemia</u>					Female	20	14.5	137.5	(84.0-212.4)
Male	10	8.3	121.2	(58.0-222.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.8	103.6	(37.8-225.6)	Female	18	18.2	98.8	(58.5-156.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.0	nc	(nc-nc)	Male	274	257.9	106.3	(94.1-119.6)
Female	1	2.4	nc	(nc-nc)	Female	278	268.2	103.6	(91.8-116.6)
<u>Lung and Bronchus</u>									
Male	34	35.6	95.6	(66.2-133.5)					
Female	42	37.8	111.2	(80.1-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	67.5	96.2	(74.3-122.7)	Male	48	44.0	109.1	(80.4-144.6)
Female	26	26.1	99.8	(65.2-146.2)	Female	29	36.9	78.5	(52.6-112.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	13.5	59.2	(25.5-116.6)	Male	12	13.9	86.4	(44.6-151.0)
Female	8	12.3	65.1	(28.0-128.3)	Female	6	12.1	49.5	(18.1-107.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.4	nc	(nc-nc)	Male	40	39.1	102.3	(73.1-139.3)
Female	280	287.4	97.4	(86.4-109.5)	Female	28	35.8	78.2	(51.9-113.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	9.8	223.5	(140.0-338.3)	Male	31	32.4	95.7	(65.0-135.8)
<u>Colon / Rectum</u>					Female	10	15.8	63.1	(30.2-116.0)
Male	61	71.3	85.5	(65.4-109.8)	<u>Ovary</u>				
Female	82	75.8	108.2	(86.0-134.3)	Female	26	25.1	103.7	(67.7-152.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	17.0	58.8	(28.1-108.1)	Male	30	25.1	119.6	(80.7-170.8)
Female	4	5.0	nc	(nc-nc)	Female	30	27.4	109.4	(73.8-156.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	5.6	nc	(nc-nc)	Male	194	201.5	96.3	(83.2-110.8)
Female	8	5.1	156.1	(67.2-307.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	22	15.9	138.2	(86.6-209.3)
Male	55	39.4	139.5	(105.1-181.6)	Female	6	10.7	56.2	(20.5-122.4)
Female	20	23.1	86.4	(52.8-133.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	11.2	80.4	(36.7-152.6)
Male	4	9.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	3.2	nc	(nc-nc)	Male	22	18.6	118.4	(74.2-179.2)
<u>Leukemia</u>					Female	70	56.3	124.4	(97.0-157.2)
Male	20	28.1	71.2	(43.5-110.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	22.0	86.5	(52.0-135.0)	Female	63	64.1	98.2	(75.5-125.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	29	24.0	121.0	(81.0-173.8)	Male	816	867.7	94.0	(87.7-100.7)
Female	8	8.7	92.1	(39.7-181.5)	Female	955	976.6	97.8	(91.7-104.2)
<u>Lung and Bronchus</u>									
Male	101	117.3	86.1	(70.1-104.6)					
Female	124	133.6	92.8	(77.2-110.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	29.5	94.8	(63.0-137.1)	Male	22	20.0	109.8	(68.8-166.2)
Female	9	10.8	83.6	(38.2-158.7)	Female	19	16.6	114.1	(68.7-178.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.3	79.9	(25.8-186.5)	Male	10	6.3	157.8	(75.5-290.2)
Female	5	5.5	90.9	(29.3-212.2)	Female	6	5.1	117.7	(43.0-256.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	19	17.7	107.0	(64.4-167.2)
Female	148	135.3	109.4	(92.5-128.5)	Female	15	15.5	96.7	(54.1-159.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.9	164.3	(70.8-323.8)	Male	18	15.5	115.9	(68.7-183.2)
<u>Colon / Rectum</u>					Female	4	7.0	nc	(nc-nc)
Male	30	32.7	91.7	(61.8-130.8)	<u>Ovary</u>				
Female	23	32.4	71.1	(45.0-106.6)	Female	15	11.3	132.4	(74.0-218.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.8	102.7	(44.2-202.4)	Male	15	11.3	132.9	(74.3-219.2)
Female	2	2.1	nc	(nc-nc)	Female	7	11.2	62.6	(25.1-129.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	96	93.9	102.3	(82.8-124.9)
Female	4	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	7.2	167.1	(86.2-291.8)
Male	15	18.8	79.8	(44.6-131.7)	Female	5	4.6	109.8	(35.4-256.2)
Female	18	10.4	173.3	(102.7-274.0)	<u>Testis</u>				
<u>Larynx</u>					Male	11	4.7	234.8	(117.0-420.1)
Male	7	4.6	153.8	(61.6-316.8)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	16	9.0	178.7	(102.1-290.2)
<u>Leukemia</u>					Female	40	27.6	145.2	(103.7-197.7)
Male	15	12.7	118.3	(66.2-195.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	9.3	nc	(nc-nc)	Female	43	29.4	146.4	(105.9-197.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	11.1	53.9	(19.7-117.3)	Male	407	396.1	102.8	(93.0-113.2)
Female	0	3.7	nc	(nc-nc)	Female	436	436.4	99.9	(90.7-109.7)
<u>Lung and Bronchus</u>									
Male	38	52.6	72.3	(51.1-99.2)					
Female	38	56.8	66.9	(47.3-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;